ArticleJournal of experimental & clinical cancer research : CR2015
Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study.
Article in Journal of experimental & clinical cancer research : CR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Male breast cancer: from extrapolated practice to evidence-based care.The oncologist · 2026Review
- A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors.Journal of translational medicine · 2025Article
- Development, verification, and comparison of a risk stratification model to identify potential population benefiting from chemotherapy in non-metastatic male breast cancer.Scientific reports · 2025Article
- The features of male breast cancer in China: A real-world study.Breast (Edinburgh, Scotland) · 2024Article
- Survival Analysis of Male Patients with Brain Metastases at Initial Breast Cancer Diagnosis over the Last Decade.Medical sciences (Basel, Switzerland) · 2024Article
- Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment.Journal of oncology · 2022Review
- An updated review of epidemiology, risk factors, and management of male breast cancer.Medical oncology (Northwood, London, England) · 2021Review
- Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).Therapeutic advances in medical oncology · 2020Article
- Male breast cancer: a disease distinct from female breast cancer.Breast cancer research and treatment · 2019Review
- Long Term Follow Up of Male Breast Cancer.The Ulster medical journal · 2017Article
- The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study.ESMO open · 2017Article
- Male Breast Cancer.The journal of breast health · 2016Review
- Establishment of Prognostic Nomogram for Male Breast Cancer Patients: A Surveillance, Epidemiology and End Results Database Analysis.Cancer control : journal of the Moffitt Cancer CenterArticle
- Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review.American journal of men's healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of chemotherapy in the treatment of metastatic male breast cancer patients remains unknown, and the only available evidence stem from small, retrospective series evaluating outdated drugs and/or regimens.
methodsIn this retrospective study we evaluated the activity of polychemotherapy, consisting of three-drug (anthracycline-containing and anthracycline-free) regimens, as a first-line therapy for metastatic male breast cancer patients who had received at least one prior endocrine therapy.
resultsFifty patients treated between 1978 and 2013 were included in the present analysis. Regarding best response, we recorded 1 (2%) complete response and 27 (54%) partial responses, for an overall response rate of 56% (95% CI, 42.2-69.8). Considering stable disease, the disease control rate was 84%. Median progression-free survival was 7.2 months (95% CI, 5.9-8.5), and median overall survival was 14.2 months (95% CI, 12.2-16.2). Albeit we observed some differences for all the outcomes explored when comparing anthracycline-containing and anthracycline-free regimens, they were not statistically significant.
conclusionsChemotherapy, consisting in both anthracycline-containing and anthracycline-free regimens, showed encouraging antitumor activity in metastatic male breast cancer patients previously treated with endocrine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.